Copper-64 (T1/2= 12.7 h) is a positron and beta-emitting isotope, with decay characteristics
suitable for both positron emission tomography (PET) imaging and radiotherapy of cancer …

Copper-64 (T1/2= 12.7 hours; β+: 19%, β−: 38%) has a unique decay profile and can be
used for positron emission tomography imaging and radionuclide therapy. The well …

Summation Copper-64 (T1/2= 12.7 hours; β+, 0.653 MeV [17.8%]; β−, 0.579 MeV [38.4%])
has decay characteristics that allow for positron emission tomography (PET) imaging and …

Copper has five radioisotopes (60Cu, 61Cu, 62Cu, 64Cu, and 67Cu) that can be used in
copper radiopharmaceuticals. These radioisotopes decay by mixed emissions of β+, β-, and …

Ongoing studies of physiological and pathological processes have led to a corresponding
need for new radiopharmaceuticals, especially when studies are limited by the absence of a …

Molecular imaging is an important scientific discipline that plays a major role in clinical
medicine and pharmaceutical development. While several imaging modalities including X …

Highlights•Copper radionuclides for in vivo imaging of biological functions of copper
ions.•Copper-64 has suitable nuclear properties for cancer theranostics.•Radioactive copper …

Copper has several clinically relevant radioisotopes and versatile coordination chemistry,
allowing attachment of its radionuclides to biological molecules. This characteristic makes it …

Copper-64 was produced in large scales and high specific activities in late 1990s' using
compact cyclotrons based by 64Ni (p, n) 64Cu reaction and many radiopharmaceuticals …

Objective Copper-64 is a useful theranostic radioisotope that is attracting renewed interest
from the nuclear medicine community in the recent times. This study aims to demonstrate the …